Trial Profile
Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- 07 May 2019 Status changed from active, no longer recruiting to completed.
- 14 Apr 2016 Planned End Date changed from 12 Feb 2016 to 1 Jun 2019.
- 07 Jan 2016 Planned End Date changed from 1 Oct 2015 to 12 Feb 2016 as reported by ClinicalTrials.gov record.